ALK gene mutation data collection to support the National Cancer Registration Service
The analysis of ALK mutations in patients with a variety of tumours underpins the appropriate allocation to treatment with tyrosine kinase inhibitors. There are a range of mutations and deletions that can activate the ALK-receptor gene and data on ALK and other molecular investigations is an increasingly important component of the clinical record on cancer patients.
The project focuses on the collection of patient-level results directly from the testing laboratories to complement the data in the National Cancer Registration Service. In the first instance collecting historical data available and then establishing regular monthly feeds on all new cases.
Sponsored by Novartis.